Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pfizer's CD3 bispecific to compete with CAR -T therapy

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Jul 29, 2023 10:55am

158 Views

Post# 35563125

RE:Pfizer's CD3 bispecific to compete with CAR -T therapy

Quoting Noteable, from Oct 2022, who was quoting a paper citing respected investigators:

Reovirus + CD3 bispecific combination .... "a true tumor-killer combo that would not be effective without each other." according to the investigators who undertook the bispecific combination study.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market